{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:13:16Z","timestamp":1792239196168,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T00:00:00Z","timestamp":1571961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s10637-019-00864-7","type":"journal-article","created":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T00:07:31Z","timestamp":1572048451000},"page":"1108-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Anthony","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saby","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Adra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreenivasulu","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur","family":"Damayanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5871-4896","authenticated-orcid":false,"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,25]]},"reference":[{"key":"864_CR1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"864_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124. https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"key":"864_CR3","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1200\/jco.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422\u20135428. https:\/\/doi.org\/10.1200\/jco.2008.16.9847","journal-title":"J Clin Oncol"},{"key":"864_CR4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1510016","journal-title":"N Engl J Med"},{"key":"864_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277\u20131290. https:\/\/doi.org\/10.1056\/NEJMoa1712126","journal-title":"N Engl J Med"},{"key":"864_CR6","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL et al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35:591\u2013597. https:\/\/doi.org\/10.1200\/JCO.2016.70.7398","journal-title":"J Clin Oncol"},{"key":"864_CR7","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256\u20134265. https:\/\/doi.org\/10.1002\/cncr.25219","journal-title":"Cancer"},{"key":"864_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2217\/thy.11.32","volume":"8","author":"C Battelli","year":"2011","unstructured":"Battelli C, Cho DC (2011) mTOR inhibitors in renal cell carcinoma. Therapy 8:359\u2013367. https:\/\/doi.org\/10.2217\/thy.11.32","journal-title":"Therapy"},{"key":"864_CR9","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.hoc.2011.04.008","volume":"25","author":"MH Voss","year":"2011","unstructured":"Voss MH, Molina AM, Motzer RJ (2011) mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 25:835\u2013852. https:\/\/doi.org\/10.1016\/j.hoc.2011.04.008","journal-title":"Hematol Oncol Clin North Am"},{"key":"864_CR10","first-page":"283","volume":"36","author":"F Lin","year":"2006","unstructured":"Lin F, Zhang PL, Yang XJ et al (2006) Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas. Ann Clin Lab Sci 36:283\u2013293","journal-title":"Ann Clin Lab Sci"},{"key":"864_CR11","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1200\/jco.2013.54.6911","volume":"32","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Barrios CH, Kim TM et al (2014) Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol 32:2765\u20132772. https:\/\/doi.org\/10.1200\/jco.2013.54.6911","journal-title":"J Clin Oncol"},{"key":"864_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1464-410X.2008.07558.x","volume":"102","author":"RS Bhatt","year":"2008","unstructured":"Bhatt RS, Landis DM, Zimmer M et al (2008) Hypoxia-inducible factor-2\u03b1: effect on radiation sensitivity and differential regulation by an mTOR inhibitor. BJU Int 102:358\u2013363. https:\/\/doi.org\/10.1111\/j.1464-410X.2008.07558.x","journal-title":"BJU Int"},{"key":"864_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1106148","volume":"307","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex. Science 307:1098\u20131101. https:\/\/doi.org\/10.1126\/science.1106148","journal-title":"Science"},{"key":"864_CR14","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1158\/1078-0432.CCR-04-1092","volume":"11","author":"XF Wang","year":"2005","unstructured":"Wang XF, Qian DZ, Ren M et al (2005) Epigenetic modulation of retinoic acid receptor \u03b22 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 11:3535\u20133542. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1092","journal-title":"Clin Cancer Res"},{"key":"864_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/1471-2407-8-381","volume":"8","author":"FR Fritzsche","year":"2008","unstructured":"Fritzsche FR, Weichert W, R\u00f6ske A et al (2008) Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer 8:381. https:\/\/doi.org\/10.1186\/1471-2407-8-381","journal-title":"BMC Cancer"},{"key":"864_CR16","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.juro.2008.04.136","volume":"180","author":"K Kanao","year":"2008","unstructured":"Kanao K, Mikami S, Mizuno R et al (2008) Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol 180:1131\u20131136. https:\/\/doi.org\/10.1016\/j.juro.2008.04.136","journal-title":"J Urol"},{"key":"864_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3109\/07357907.2011.590568","volume":"29","author":"JD Hainsworth","year":"2011","unstructured":"Hainsworth JD, Infante JR, Spigel DR et al (2011) A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Investig 29:451\u2013455. https:\/\/doi.org\/10.3109\/07357907.2011.590568","journal-title":"Cancer Investig"},{"key":"864_CR18","doi-asserted-by":"publisher","first-page":"197946","DOI":"10.1155\/2011\/197946","volume":"2011","author":"S Chen","year":"2011","unstructured":"Chen S, Sang N (2011) Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol 2011:197946. https:\/\/doi.org\/10.1155\/2011\/197946","journal-title":"J Biomed Biotechnol"},{"key":"864_CR19","doi-asserted-by":"publisher","first-page":"13612","DOI":"10.1074\/jbc.M600456200","volume":"281","author":"DM Fath","year":"2006","unstructured":"Fath DM, Kong X, Liang D et al (2006) Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-\u03b1. J Biol Chem 281:13612\u201313619. https:\/\/doi.org\/10.1074\/jbc.M600456200","journal-title":"J Biol Chem"},{"key":"864_CR20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/2040620714552614","volume":"5","author":"CV Andreu-Vieyra","year":"2014","unstructured":"Andreu-Vieyra CV, Berenson JR (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Ther Adv Hematol 5:197\u2013210. https:\/\/doi.org\/10.1177\/2040620714552614","journal-title":"Ther Adv Hematol"},{"key":"864_CR21","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-07-4306","volume":"14","author":"HMW Verheul","year":"2008","unstructured":"Verheul HMW, Salumbides B, Van Erp K et al (2008) Combination strategy targeting the hypoxia inducible factor-1 \u03b1 with mammalian target of rapamycin and histone deacetylase inhibitors. Clin Cancer Res 14:3589\u20133597. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4306","journal-title":"Clin Cancer Res"},{"key":"864_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VTM, Yoon SS et al (2014) Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 15:1195\u20131206. https:\/\/doi.org\/10.1016\/S1470-2045(14)70440-1","journal-title":"Lancet Oncol"},{"key":"864_CR23","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.molonc.2012.09.006","volume":"6","author":"MD Jansson","year":"2012","unstructured":"Jansson MD, Lund AH (2012) MicroRNA and cancer. Mol Oncol 6:590\u2013610. https:\/\/doi.org\/10.1016\/j.molonc.2012.09.006","journal-title":"Mol Oncol"},{"key":"864_CR24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/emboj.2010.347","volume":"30","author":"J Xiao","year":"2011","unstructured":"Xiao J, Lin H, Luo X et al (2011) miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress. EMBO J 30:524\u2013532. https:\/\/doi.org\/10.1038\/emboj.2010.347","journal-title":"EMBO J"},{"key":"864_CR25","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1016\/j.febslet.2014.08.008","volume":"588","author":"J Li","year":"2014","unstructured":"Li J, Tian F, Li D et al (2014) MiR-605 represses PSMD10\/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett 588:3491\u20133500. https:\/\/doi.org\/10.1016\/j.febslet.2014.08.008","journal-title":"FEBS Lett"},{"key":"864_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.lfs.2017.09.028","volume":"190","author":"YJ Zhou","year":"2017","unstructured":"Zhou YJ, Yang HQ, Xia W et al (2017) Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. Life Sci 190:7\u201314. https:\/\/doi.org\/10.1016\/j.lfs.2017.09.028","journal-title":"Life Sci"},{"key":"864_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40880-016-0136-9","volume":"35","author":"L Miao","year":"2016","unstructured":"Miao L, Wang L, Zhu L et al (2016) Association of microRNA polymorphisms with the risk of head and neck squamous cell carcinoma in a Chinese population: a case-control study. Chin J Cancer 35:77. https:\/\/doi.org\/10.1186\/s40880-016-0136-9","journal-title":"Chin J Cancer"},{"key":"864_CR28","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s10637-015-0261-3","volume":"33","author":"M Zibelman","year":"2015","unstructured":"Zibelman M, Wong YN, Devarajan K et al (2015) Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Investig New Drugs 33:1040\u20131047. https:\/\/doi.org\/10.1007\/s10637-015-0261-3","journal-title":"Investig New Drugs"},{"key":"864_CR29","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1200\/JCO.2007.14.5482","volume":"26","author":"J Tabernero","year":"2008","unstructured":"Tabernero J, Rojo F, Calvo E et al (2008) Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26:1603\u20131610. https:\/\/doi.org\/10.1200\/JCO.2007.14.5482","journal-title":"J Clin Oncol"},{"key":"864_CR30","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/bjc.2017.33","volume":"116","author":"R Pili","year":"2017","unstructured":"Pili R, Liu G, Chintala S et al (2017) Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I\/II clinical trial. Br J Cancer 116:874\u2013883. https:\/\/doi.org\/10.1038\/bjc.2017.33","journal-title":"Br J Cancer"},{"key":"864_CR31","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1200\/JCO.2016.70.5350","volume":"35","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Thomas S, Pawlowska N et al (2017) Inhibiting histone deacetylase as a means to reverse resistance to angiogenesis inhibitors: phase I study of abexinostat plus pazopanib in advanced solid tumor malignancies. J Clin Oncol 35:1231\u20131239. https:\/\/doi.org\/10.1200\/JCO.2016.70.5350","journal-title":"J Clin Oncol"},{"key":"864_CR32","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1158\/1078-0432.CCR-17-1178","volume":"23","author":"R Pili","year":"2017","unstructured":"Pili R, Quinn DI, Hammers HJ et al (2017) Immunomodulation by entinostat in renal cell carcinoma patients receiving high-dose interleukin 2: a multicenter, single-arm, phase I\/II trial (NCI-CTEP#7870). Clin Cancer Res 23:7199\u20137208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1178","journal-title":"Clin Cancer Res"},{"key":"864_CR33","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/1078-0432.CCR-17-0741","volume":"23","author":"A Orillion","year":"2017","unstructured":"Orillion A, Hashimoto A, Damayanti N et al (2017) Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res 23:5187\u20135201. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0741","journal-title":"Clin Cancer Res"},{"key":"864_CR34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473\u20131482. https:\/\/doi.org\/10.1016\/S1470-2045(15)00290-9","journal-title":"Lancet Oncol"},{"key":"864_CR35","doi-asserted-by":"publisher","unstructured":"Morales S, De Mayo T, Gulppi FA et al (2018) Genetic variants in pre-miR-146a, pre-miR-499, pre-miR-125a, pre-miR-605, and pri-miR-182 are associated with breast cancer susceptibility in a south American population. Genes (Basel) 9. https:\/\/doi.org\/10.3390\/genes9090427","DOI":"10.3390\/genes9090427"},{"key":"864_CR36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/2211536608666181204110508","volume":"8","author":"A Moazeni-Roodi","year":"2019","unstructured":"Moazeni-Roodi A, Ghavami S, Hashemi M (2019) Lack of association between miR-605 rs2043556 polymorphism and overall cancer risk: a meta-analysis of case-control studies. Microrna 8:94\u2013100. https:\/\/doi.org\/10.2174\/2211536608666181204110508","journal-title":"Microrna"},{"key":"864_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/mutage\/gez005","volume":"34","author":"S Wang","year":"2019","unstructured":"Wang S, Zhu H, Ding B et al (2019) Genetic variants in microRNAs are associated with cervical cancer risk. Mutagenesis 34:127\u2013133. https:\/\/doi.org\/10.1093\/mutage\/gez005","journal-title":"Mutagenesis"},{"key":"864_CR38","doi-asserted-by":"publisher","unstructured":"Hu M, Yu Z, Luo D et al (2018) Association between the polymorphism in miR-605 and cancer susceptibility: a PRISMA-compliant meta-analysis. Clin Lab 64. https:\/\/doi.org\/10.7754\/Clin.Lab.2018.180545","DOI":"10.7754\/Clin.Lab.2018.180545"},{"key":"864_CR39","unstructured":"Miller M, Shirole N, Tian R et al (2016) The evolution of TP53 mutations: from loss-of-function to separation-of-function mutants. J Cancer Biol Res 4(4)"},{"key":"864_CR40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cancergen.2014.12.003","volume":"208","author":"B Id Said","year":"2015","unstructured":"Id Said B, Malkin D (2015) A functional variant in miR-605 modifies the age of onset in Li-Fraumeni syndrome. Cancer Genet 208:47\u201351. https:\/\/doi.org\/10.1016\/j.cancergen.2014.12.003","journal-title":"Cancer Genet"},{"key":"864_CR41","doi-asserted-by":"publisher","first-page":"83913","DOI":"10.18632\/oncotarget.19996","volume":"8","author":"J Lawson","year":"2017","unstructured":"Lawson J, Dickman C, MacLellan S et al (2017) Selective secretion of microRNAs from lung cancer cells via extracellular vesicles promotes CAMK1D-mediated tube formation in endothelial cells. Oncotarget 8:83913\u201383924. https:\/\/doi.org\/10.18632\/oncotarget.19996","journal-title":"Oncotarget"},{"key":"864_CR42","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1091\/mbc.E17-03-0176","volume":"28","author":"M Gendarme","year":"2017","unstructured":"Gendarme M, Baumann J, Ignashkova TI et al (2017) Image-based drug screen identifies HDAC inhibitors as novel golgi disruptors synergizing with JQ1. Mol Biol Cell 28:3756\u20133772. https:\/\/doi.org\/10.1091\/mbc.E17-03-0176","journal-title":"Mol Biol Cell"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00864-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00864-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00864-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:40:58Z","timestamp":1678509658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00864-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,25]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["864"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00864-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,25]]},"assertion":[{"value":"28 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Anthony Wood declares that he has no conflict of interest. Saby George declares that he has no conflict of interest. Nabil Adra declares that he has no conflict of interest. Sreenivasulu Chintala declares that he has no conflict of interest. Nur Damayanti declares that she has no conflict of interest. Roberto Pili declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}